← MAIA Biotechnology, Inc. (MAIA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
MAIA Biotechnology, Inc. (MAIA)
Pharmaceutical Preparations · market cap $82M · as of 2026-07-15
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-06 (est.)
Earnings
Pipeline
2
programs
Upcoming events
4
next 90d+
Dossier
Ready
cached
MAIA Biotechnology (MAIA) is a Chicago-based, 13-employee immuno-oncology company with an $88M market cap focused on telomere-targeting agents for telomerase-positive cancers. Its pipeline centers on two Phase 3 assets in non-small-cell lung cancer (NSCLC): cemiplimab (a PD-1 inhibitor licensed from Regeneron) and 6-thio-2'-deoxyguanosine (6-TdG), its proprietary telomere-targeting nucleoside analogue. The company reported $0M cash and zero runway per the most recent financial disclosure, raising acute financing risk.
The catalyst path
- 2026-11-06 (est.)Earningsimp 5/10
- 2027-07-31 (est.)Phase 3 · Vinorelbineimp 9/10
- 2027-09-30 (est.)Phase 3 · 6-Thio-2'-Deoxyguanosineimp 9/10
- 2027-09-30 (est.)Phase 2 · 6-Thio-2'-Deoxyguanosineimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| 6-Thio-2'-Deoxyguanosine | Phase 3 | Carcinoma, Non-Small-Cell Lung |
| Vinorelbine | Phase 3 | Carcinoma, Non-Small -Cell Lung |
Price & technical context
3-month
-19.3%
6-month
-12.7%
12-month
-24.0%
52-wk range
$0.87–$2.95
vs 50-day MA
-11.7%
vs 200-day MA
-21.6%
Realized vol
89.6%
Max drawdown
-75.0%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for MAIA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.